Literature DB >> 14669968

Effect of orlistat on fat absorption in rats: a comparison of normal rats and rats with diverted bile and pancreatic juice.

Trine Porsgaard1, Ellen Marie Straarup, Huiling Mu, Carl-Erik Høy.   

Abstract

Orlistat is a specific inhibitor of pancreatic and gastric lipases leading to decreased absorption of fat. In the present study, we measured the effect of orlistat on lymphatic fat transport in rats following intake of oils very different in FA composition and TAG structure, and compared this with the transport in normal rats and rats with fat malabsorption. Rats were subjected to cannulation of the main mesenteric lymph duct, and a feeding catheter was inserted into the stomach. In addition, malabsorbing rats were cannulated in the common bile and pancreatic duct. Emulsified safflower, fish, and randomized oils were administered, and lymph was collected for 24 h and analyzed for FA composition. Administration of 25 mg orlistat together with the dietary oils resulted in very small changes from baseline lymphatic transport, indicating that inhibition of the fat absorption was almost complete and furthermore that the source of fat had no influence on the inhibitory effect of orlistat. Orlistat did not interfere with the absorption of the hydrolysis products, since high absorption of sn-2 MAG and FFA (oleic acid) mixed with orlistat was observed. The baseline lymphatic transport in the orlistat group was higher than in the malabsorbing group, but this was the result of generally lower transport of endogenous FA in the malabsorbing group, presumably caused by the absence of bile FA. The transport of FA in normal rats was several-fold higher than the transport after orlistat addition and in malabsorbing rats. Thus, this study showed that orlistat inhibited fat hydrolysis, and thereby lymphatic absorption, almost completely independently of the fat administered.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14669968     DOI: 10.1007/s11745-006-1158-x

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  21 in total

1.  Effects of tetrahydrolipstatin, a lipase inhibitor, on absorption of fat from the intestine of the rat.

Authors:  E Fernandez; B Borgström
Journal:  Biochim Biophys Acta       Date:  1989-02-20

Review 2.  Lingual and gastric lipases.

Authors:  M Hamosh
Journal:  Nutrition       Date:  1990 Nov-Dec       Impact factor: 4.008

3.  One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.

Authors:  N Finer; W P James; P G Kopelman; M E Lean; G Williams
Journal:  Int J Obes Relat Metab Disord       Date:  2000-03

4.  Orlistat in the long-term treatment of obesity in primary care settings.

Authors:  J Hauptman; C Lucas; M N Boldrin; H Collins; K R Segal
Journal:  Arch Fam Med       Date:  2000-02

5.  Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers.

Authors:  J Zhi; A T Melia; R Guerciolini; J Chung; J Kinberg; J B Hauptman; I H Patel
Journal:  Clin Pharmacol Ther       Date:  1994-07       Impact factor: 6.875

6.  Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity.

Authors:  E K Weibel; P Hadvary; E Hochuli; E Kupfer; H Lengsfeld
Journal:  J Antibiot (Tokyo)       Date:  1987-08       Impact factor: 2.649

7.  The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase.

Authors:  P Hadváry; W Sidler; W Meister; W Vetter; H Wolfer
Journal:  J Biol Chem       Date:  1991-02-05       Impact factor: 5.157

8.  Absorption and intestinal catabolism of fatty acids in the rat: effect of chain length and unsaturation.

Authors:  A Bernard; H Carlier
Journal:  Exp Physiol       Date:  1991-05       Impact factor: 2.969

9.  Effect of the lipase inhibitor orlistat and of dietary lipid on the absorption of radiolabelled triolein, tri-gamma-linolenin and tripalmitin in mice.

Authors:  D Isler; C Moeglen; N Gains; M K Meier
Journal:  Br J Nutr       Date:  1995-06       Impact factor: 3.718

10.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Authors:  M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.